Voranigo Continues to Benefit Patients With Grade 2 IDH-Mutated GliomaBySpencer FeldmanNovember 4th 2025
What Dermatological Side Effects Can Patients With Breast Cancer Expect?ByAlex BieseOctober 28th 2025
FDA Grants Rare Pediatric Designation for Iopofosine-131 in Glioma SubsetBySpencer FeldmanOctober 27th 2025